Intuitive Surgical ISRG delivered robust 2025 results, beating estimates on both counts. Total revenues rose 20.5% year over ...

Intuitive Surgical received FDA clearance for its da Vinci 5 system in selected cardiac procedures, including mitral valve ...

The FDA 510(k) clearances for cardiac procedures cover Intuitive's latest-generation da Vinci 5 (DV5) using non-Force ...

With nine new procedures cleared for the da Vinci 5 robot, Intuitive’s strategy includes working with a limited number of U.S ...

Intuitive Surgical (NasdaqGS:ISRG) received FDA clearance for its da Vinci 5 system to be used in certain cardiac procedures.

Intuitive Surgical receives FDA clearance for the da Vinci 5 robot to be used in cardiac procedures, reports 18% procedure ...

Artificial intelligence isn't performing surgery yet, but if (when?) it does, these two companies are likely to be at the ...

Intuitive Surgical (NASDAQ: ISRG) reports in-line Q4 results, sets measured guidance for 2026, with an 18% revenue growth and $2.53 EPS.

Intuitive Surgical's 2025 earnings were strong, and the future remains bright, with valuation as the only big concern for investors.

Intuitive Surgical's third-quarter earnings beat expectations with 23% sales growth, and earnings of $2.40 per share versus $1.99 expected. The stock trades at 72 times earnings, which sounds ...

Intuitive Surgical Inc (NASDAQ:ISRG) reports financial results for the fourth quarter on Thursday. Here's a rundown of the report.